HC Wainwright & Co. Downgrades Aclaris Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Aclaris Therapeutics (NASDAQ:ACRS) from Buy to Neutral, indicating a change in the firm's outlook on the stock.

January 22, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aclaris Therapeutics was downgraded by HC Wainwright & Co. from Buy to Neutral, which may lead to a negative perception among investors and could impact the stock price in the short term.
Downgrades by analysts can often lead to a short-term negative reaction in the stock market as they may reflect a less optimistic view on the company's future performance or valuation. Given that this is a direct rating change by a known analyst firm, it is likely to be taken seriously by investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100